The use of a pill containing ethinylestradiol-norgestimate improves female sexuality despite the decrease in circulating androgens: a pilot study.
Eur J Contracept Reprod Health Care
; 29(4): 160-162, 2024 Aug.
Article
en En
| MEDLINE
| ID: mdl-38940613
ABSTRACT
PURPOSE:
To evaluate the initial impact of a combined oral contraceptive (COC) containing norgestimate (NGM) on female sexuality and on circulating androgen levels in users. MATERIALS ANDMETHODS:
Six months modification in the McCoy Female Sexuality Questionnaire (MFSQ) and testosterone (T) and dehydroepiandrosterone sulphate (DHEAS) serum levels in women starting a monophasic pill containing ethinyl-estradiol (EE) 35 µg and NGM 0.250 mg.RESULTS:
The study was completed by 36 subjects. There was a significant increase in MFSQ during treatment (p < 0.0001) (and its domains with the exclusion of vaginal lubrication domain) with concomitant decreases in T (-4.45%, p < 0.0001) and DHEAS (-19.41%, p < 0.0001) serum levels.CONCLUSIONS:
Contraception with EE/NGM was associated with a short term non-deteriorating effect on sexuality despite the evident decrease in androgen levels. Female sexuality during COC use is a complex topic and is not only linked with changes in serum androgen levels.Palabras clave
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Testosterona
/
Anticonceptivos Orales Combinados
/
Etinilestradiol
Límite:
Adult
/
Female
/
Humans
Idioma:
En
Revista:
Eur J Contracept Reprod Health Care
Asunto de la revista:
MEDICINA REPRODUTIVA
/
SERVICOS DE PLANEJAMENTO FAMILIAR
Año:
2024
Tipo del documento:
Article
País de afiliación:
Italia